Pandit Kaushik, Mukhopadhyay Pradip, Ghosh Sujoy, Chowdhury Subhankar
Department of Endocrinology, Institute of Post Graduate Medical Education and Research and S.S.K.M. Hospital, Kolkata, India.
Indian J Endocrinol Metab. 2011 Oct;15 Suppl 4(Suppl4):S345-53. doi: 10.4103/2230-8210.86978.
Natriuretic peptides (NPs) are hormones which are mainly secreted from heart and have important natriuretic and kaliuretic properties. There are four different groups NPs identified till date [atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and dendroaspis natriuretic peptide, a D-type natriuretic peptide (DNP)], each with its own characteristic functions. The N-terminal part of the prohormone of BNP, NT-proBNP, is secreted alongside BNP and has been documented to have important diagnostic value in heart failure. NPs or their fragments have been subjected to scientific observation for their diagnostic value and this has yielded important epidemiological data for interpretation. However, little progress has been made in harnessing the therapeutic potential of these cardiac hormones.
利钠肽（NPs）是主要由心脏分泌的激素，具有重要的利钠和利尿特性。迄今为止，已鉴定出四种不同类型的利钠肽[心房利钠肽（ANP）、B型利钠肽（BNP）、C型利钠肽（CNP）和树眼镜蛇利钠肽，一种D型利钠肽（DNP）]，每种都有其独特的功能。BNP前体激素的N端部分，即NT-proBNP，与BNP一起分泌，并且已被证明在心力衰竭中具有重要的诊断价值。利钠肽或其片段因其诊断价值而受到科学观察，这产生了重要的流行病学数据以供解读。然而，在利用这些心脏激素的治疗潜力方面进展甚微。
